Background and Aim
The recent clinical success of immune checkpoint modulators has stimulated immune-oncology research leading to the identification of new tumor immunology targets. However both, target validation and drug development need better preclinical immune oncology models with functional human immune cells. In previous experiments, we have demonstrated, that hematopoietic stem cells (HSC) can proliferate and differentiate in vivo to form a functional humanized immune system. Based on this, we determined PD-L1 expression as a target for immunotherapy on different tumor cell lines (CDX) and patient-derived xenografts (PDX). PD-L1 positive and negative models were selected and co-transplanted on humanized mice. Finally, we evaluated the functionality of the human immune system by the treatment with the checkpoint inhibitors Ipilimumab or Nivolumab and in combination with radiation.
Summary and Outlook
We reconstituted a functional human immune system by engrafting human hematopoetic stem cells in immunodeficient mice.
Repopulation of mouse organs with human hematopoetic cells and maturation of human T and B cells has been demonstrated.
CDX and PDX showed a heterogenous expression of PD-L1 expression comparable to clinical situation in humans.
Fragments from CDX and PDX of different entities were successfully engrafted on our humanized mice.
Delayed tumor growth in humanized mice seems to be in correlation with PD-L1 expression.
Strong response to checkpoint inhibitors showed a correlation to innate immune response without treatment and to PD-L1 expression in tumors.
Our humanized mouse models enable appropriate preclinical assessment of immune-based therapeutic antitumor strategies plus radiation especially when combining the humanized mouse with cell-and patient-derived tumor xenografts. * differential expression of PD-L1 in PDX models of different entities * PD-L1 expression correlated mostly between patient samples and passages of PDX * in most cases, high expression of PD-L1 on RNA level could also detected on protein level in investigated PDX Characterization of cell line -derived xenografts (CDX) Humanization of mice with hematopoetic stem cells (HSC) from cord blood * differential expression of PD-L1 in CDX models * gene expression data for CDX models of different entities are available on our website -www.epo-berlin.com Ovcar 
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